You are here

Study Bodes Well for Biosimilars

Biosimilar TNF inhibitors are interchangeable with original versions, authors find

Researchers at Johns Hopkins University and Brigham and Women’s Hospital have found comparable efficacy and safety among biosimilar tumor necrosis factor (TNF)-alpha inhibitors, according to a report from Kaiser Health News. TNF inhibitors are commonly used to treat inflammation in patients with rheumatoid arthritis or inflammatory bowel disease.

The researchers reviewed 19 studies to determine how these biosimilars compared with their brand-name counterparts, focusing on efficacy and safety. They found that the biosimilars were “interchangeable” with the original versions, such as infliximab (Remicade, Janssen Biotech) and adalimumab (Humira, AbbVie). Their findings were published online in the Annals of Internal Medicine.

Co-author G. Caleb Alexander, MD, and his team studied overall patient outcomes, adverse events, and whether patients had immune-system reactions to the drugs. Approximately 1,400 subjects took part in the clinical trials, and more than 500 were included in observational studies that made up the meta-analysis. They concluded that preliminary evidence supports the biosimilarity and interchangeability of biosimilar and reference TNF-alpha inhibitors.

Study limitations included possible publication bias, the small sample sizes of many studies, and the lack of published studies for several biosimilars.

Since their arrival on the market, biologics have been major moneymakers for drug companies, according to the Kaiser report. AbbVie, for example, saw its quarterly net revenue jump by 18% in earnings reported last week, thanks to its biosimilar adalimumab.

The FDA approved its first biosimilar, Zarxio (filgrastim-sndz, Sandoz), which is used to treat chemotherapy-associated infections, in September 2015. And in April, the FDA gave the green light to a Remicade biosimilar, Inflectra (infliximab-dyyb, Celltrion/Hospira).

Inflectra has not yet launched in the United States, but in Europe, where it was approved in 2013, it reportedly costs approximately 30% less than the original drug. Zarxio was approximately 15% cheaper than its precursor, Neupogen (Amgen), when it launched in Europe in 2009.

Source: Kaiser Health News; August 2, 2106; and Annals of Internal Medicine; August 2, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress